44 results on '"Jessup J"'
Search Results
2. Data from Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition
3. Supplementary Figures 1-6, Supplemental Table 1 from Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition
4. Supplementary Figures 1-6, Supplemental Table 1 from Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition
5. Supplementary Figures 1 - 3, Table 1 from Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
6. Supplemental Figure Legend from Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
7. Supplementary Table S2: Clinical trials in myeloma using MRD assessments from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
8. Supplementary Figures S1 and S2: Association of MRD with survival outcomes in myeloma patients from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
9. Supplementary Figure 2 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
10. Supplementary Figure 4 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
11. Supplementary Figure 2 from Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling
12. Supplementary Figure 1 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
13. Supplementary Figure 3A from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
14. Supplementary Figure 1 from Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling
15. Supplementary Figure 5 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
16. Supplementary Figure 3B from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
17. Supplementary Figure 5 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
18. Supplementary Figure 3 from Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling
19. Supplementary Figure 2 from Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling
20. Supplementary Figure 3A from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
21. Supplementary Figure 1 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
22. Supplementary Figure 3B from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
23. Supplementary Figure 1 from Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling
24. Supplementary Legends 1-5 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
25. Supplementary Figure 3 from Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling
26. Supplementary Legends 1-5 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
27. Supplementary Figure 2 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
28. Supplementary Figure 4 from DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
29. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition
30. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
31. Abstract 2335: Targeting the DNA repair as well as survival functions of MCL-1 enhances cancer cell killing
32. Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
33. Abstract 339: Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer (CRC) cells, enhances the efficacy of BH3 mimetics and inhibits clonogenicity
34. Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer
35. Abstract 5646: Allele-specific shRNA to Nanog family members inhibits 3-D growth of colorectal carcinoma through the intrinsic apoptotic pathway
36. Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031
37. Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use
38. Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development
39. Abstract 5206: Nanog family members are essential for spherogenicity and metastasis in colorectal carcinoma
40. Abstract 4249: Shape change induces nitric oxide and stemness in colorectal cancer cells
41. Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
42. DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
43. Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling
44. Nitrosative Stress in Rotated Three-Dimensional Colorectal Carcinoma Cell Cultures Induces Microtubule Depolymerization and Apoptosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.